Back to Agenda
Session 8: Evaluation and Selection Criteria
Session Chair(s)
Dan Milam, MBA
Vice President, Global Engagement
Society for Clinical Research Sites, United States
Site selection and feasibility, like many aspects of our work has changed significantly. Not only is selection criteria becoming much more specific, but the trials are becoming more complex - this means a narrower funnel for sites who are being asked to perform more tasks within a trial. This is coupled with the fact that digital technology is also having a significant impact on the site selection and feasibility process. Sponsors and CROs are using complex programs to better and more accurately assess sites for selection, and site are beginning to utilize technology more and more to find these specific patients they need within their own databases, or when assessing feasibility in an often rapid manner. This panel will address this change and how it is impacting our industry, as well as how technology is altering how site selection and feasibility criteria are determined and tracked against potential patients.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Identification and understanding of how site selection and feasibility criteria have changed and will continue to change
- How technology has impacted this process
- What opportunities exist for efficiencies utilizing technology for from the site, service provider, and CRO prospective
Speaker(s)
Speaker
Ahmad Namvargolian, MPA
Care Access, United States
Chief Executive Officer & Co-founder
Speaker
Cindy Howry, MS
assisTek, United States
President
Speaker
Marisa Rackley, MHA
Vertex Pharmaceuticals, United States
Director Global Operations
Speaker
Todd Albin
Cedar Health Research, United States
Chief Executive Officer
Have an account?